EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Molecular mechanisms responsible for transglutaminase 2 involvement in the multiple sclerosis etiopathogenesis and its possible use as a neuroinflammation biomarker

Rosa Giacca, Maria Preziosi, Vittorio Gentile

Eurasian Journal of Medicine and Oncology · 2026-09-15 · 10 (5) · 026170189

DOI: 10.36922/ejmo026170189 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Transglutaminase 2 (TG2) is a ubiquitous enzyme involved in extracellular matrix remodeling, cell adhesion, signal transduction, and modulation of immune responses. While its role in celiac disease is well established, increasing evidence supports its involvement in the pathogenesis of multiple sclerosis (MS). Objectives: The objectives of this review are to describe the molecular mechanisms responsible for TG2 involvement in the multiple sclerosis etiopathogenesis and to evaluate its potential as a neuroinflammation biomarker. Methods: The literature on the involvement of TG2 in MS was reviewed, with particular attention to its molecular mechanisms, expression in central and peripheral immune cells, association with disease activity and progression, and potential role as a biomarker of neuroinflammation. Results: TG2 has been detected in monocytes and macrophages within demyelinating lesions, is induced in astrocytes by pro-inflammatory mediators, and is expressed in neurons and endothelial cells under neuroinflammatory conditions. Its localization in astrocytes within MS plaques further supports a role in sustaining neuroinflammation. Modulation of TG2 activity influences immune cell trafficking across the blood–brain barrier and regulates microglial and macrophage polarization. In patients with MS, altered TG2 expression and splicing isoforms in peripheral blood mononuclear cells are associated with disease activity, progression, and specific monocytic functional profiles. Preliminary findings in individuals with radiologically isolated syndrome suggest that peripheral TG2 expression may serve as an indicator of subclinical neuroinflammation. Conclusion: Overall, TG2 emerges as a promising biomarker in MS, potentially complementing established neuroaxonal markers and improving phenotypic stratification. Further validation of its diagnostic and prognostic value will require large prospective studies integrating multi-omics approaches and advanced neuroimaging within a precision medicine framework.  

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →